VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB:EHVVF) (“Ehave”), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.
“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to
... read more at: https://globenewswire.com/news-release/2018/03/05/1414939/0/en/Aequus-and-Ehave-Enter-Into-Collaboration-Agreement-for-Comprehensive-Patient-Data-Management-in-Clinical-Trials-of-Medical-Cannabis.html